Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN93,7693,80,38
Msft-0,72
Nokia4,624,6395-0,89
IBM-0,83
Daimler AG48,15548,175-1,01
PFE-0,22
17.09.2019 8:00:18
Indexy online
AD Index online
select
AD Index online
 

  • 16.09.2019
Abbott Labs (ABT, NY Consolidated)
Závěr k 16.9.2019 Změna (%) Změna (USD) Objem obchodů (ks)
83,36 -1,08 -0,91 3 991 210
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.09.2019
Popis společnosti
Obecné informace
Název společnostiAbbott Laboratories
TickerABT
Kmenové akcie:Ordinary Shares
RICABT
ISINUS0028241000
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.06.2019
Počet zaměstnanců k 31.12.2018 103 000
Akcie v oběhu k 30.06.20191 767 397 615
Počet akcionářů k 31.12.2018 42 827
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice100 Abbott Park Rd
MěstoABBOTT PARK
PSČ60064-3500
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 246 676 100

Business Summary: Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Financial Summary: BRIEF: For the six months ended 30 June 2019, Abbott Laboratories revenues increased 2% to $15.51B. Net income before extraordinary items increased 40% to $1.6B. Revenues reflect Other segment increase of 31% to $1.2B, Vascular Products segment increase of 1% to $4.8B, Nutritionals segment increase of 1% to $3.67B, United States segment increase of 4% to $5.6B, All other Countries segment increase of 1% to $9.91B.
Odvětvová klasifikace
TRBC2012Medical Equipment
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSInVitro Diagnostic Substance Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSDrug, Drug Proprietaries and Druggists' Sundries Wholesalers
NAICSMedical, Dental and Hospital Equipment and Supplies Wholesalers
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICElectromedical Equipment
SICMedicinals And Botanicals
SICDiagnostic Substances
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries
SICMedical And Hospital Equipment
SICCommercial Physical Research



  • Poslední aktualizace: 17.09.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerMiles White6401.01.1993
President, Chief Operating OfficerRobert Ford4515.10.201801.01.2014
Chief Financial Officer, Executive Vice President - FinanceBrian Yoor4901.06.2015
Executive Vice President, General Counsel, SecretaryHubert Allen53
Senior Vice President - Core Laboratory Diagnostics, Commercial OperationsJaime Contreras6201.01.2003
Senior Vice President - Established Pharmaceuticals, Latin America.Daniel Salvadori4001.01.2014